Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN171H in Pulmonary Arterial Hypertension
NCT04483115Phase 2Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TPN171H in pulmonary arterial hypertension (PAH), sponsored by Vigonvita Life Sciences. Started Nov 2020; status: completed.
02
Drugs
TPN171H
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04483115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483115.